Novel Pentapeptide GLP-1 (32-36) Amide Inhibitsβ-Cell ApoptosisIn Vitroand Improves Glucose Disposal in Streptozotocin-Induced Diabetic Mice

Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolongedin vivoglucose-lowering ability

(2014) Jing Han et al.   BRITISH JOURNAL OF PHARMACOLOGY

GLP-1(28–36) improves β-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP/PKA/β-catenin signaling in β-cells in vitro

(2013) Weijuan Shao et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

GLP-1-derived nonapeptide GLP-1(28–36)amide represses hepatic gluconeogenic gene expression and improves pyruvate tolerance in high-fat diet-fed mice

(2013) Wilfred Ip et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Evaluation of Hypoglycemic and Antioxidative Effects of Synthesized Peptide MC62

(2013) Baowei Yang et al.   Chemical Biology & Drug Design

Incretin-based therapies: can we achieve glycemic control and cardioprotection?

(2013) Franca S Angeli et al.   JOURNAL OF ENDOCRINOLOGY

Design, Synthesis, and Biological Activity of Novel Dicoumarol Glucagon-like Peptide 1 Conjugates

(2013) Jing Han et al.   JOURNAL OF MEDICINAL CHEMISTRY

Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders

(2012) Isidro Salcedo et al.   BRITISH JOURNAL OF PHARMACOLOGY

GLP1-derived nonapeptide GLP1(28–36)amide protects pancreatic β-cells from glucolipotoxicity

(2012) Zhengu Liu et al.   JOURNAL OF ENDOCRINOLOGY

Stromal cell-derived factor-1 (SDF-1)/chemokine (C-X-C motif) receptor 4 (CXCR4) axis activation induces intra-islet glucagon-like peptide-1 (GLP-1) production and enhances beta cell survival

(2011) Z. Liu et al.   DIABETOLOGIA

GLP-1-derived nonapeptide GLP-1(28–36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes

(2011) Eva Tomas et al.   REGULATORY PEPTIDES

GLP-1-derived nonapeptide GLP-1(28–36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice

(2011) Eva Tomas et al.   REGULATORY PEPTIDES

Overview of Newer Agents: Where Treatment Is Going

(2010) Ralph A. DeFronzo   AMERICAN JOURNAL OF MEDICINE

Glucagon-like peptide-1(9-36)amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice

(2010) E. Tomas et al.   DIABETES OBESITY & METABOLISM

Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor

(2010) Kiwon Ban et al.   ENDOCRINOLOGY

GLP-1 (9–36) Amide Metabolite Suppression of Glucose Production in Isolated Mouse Hepatocytes

(2010) E. Tomas et al.   HORMONE AND METABOLIC RESEARCH

The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides

(2009) Rania Abu-Hamdah et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis

(2009) Eva Tomas et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

(2008) Kiwon Ban et al.   CIRCULATION

GLP-1 (9-36) Amide, Cleavage Product of GLP-1 (7-36) Amide, Is a Glucoregulatory Peptide

(2008) Dariush Elahi et al.   Obesity